{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:15:58Z","timestamp":1781907358973,"version":"3.54.5"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"China Natural Science","award":["31670921"],"award-info":[{"award-number":["31670921"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.intimp.2018.05.020","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T02:52:02Z","timestamp":1528339922000},"page":"178-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-9622","authenticated-orcid":false,"given":"Zijian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3877-5293","authenticated-orcid":false,"given":"Yue","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengping","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2018.05.020_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life","volume":"72","author":"Brown","year":"2009","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.intimp.2018.05.020_bb0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1258\/ebm.2011.011096","article-title":"Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin","volume":"236","author":"Donahue","year":"2011","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0015","series-title":"The Use of Naltrexone in Low Doses Beyond the Approved Indication","article-title":"NIPH systematic reviews: executive summaries","author":"Ringerike","year":"2015"},{"key":"10.1016\/j.intimp.2018.05.020_bb0020","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/BF02532375","article-title":"Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence","volume":"21","author":"Crain","year":"1996","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drugalcdep.2004.02.003","article-title":"A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence","volume":"75","author":"Rea","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.intimp.2018.05.020_bb0030","first-page":"Cd006140","article-title":"Sustained-release naltrexone for opioid dependence","author":"Lobmaier","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2018.05.020_bb0035","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/jnr.20738","article-title":"Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats","volume":"83","author":"Van Bockstaele","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2013.05.030","article-title":"Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?","volume":"133","author":"Sullivan","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.intimp.2018.05.020_bb0045","first-page":"685","article-title":"Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database","volume":"26","author":"Raknes","year":"2017"},{"key":"10.1016\/j.intimp.2018.05.020_bb0050","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/pme.12704","article-title":"Low-dose naltrexone to prevent intolerable morphine adverse events: a forgotten remedy for a neglected, global clinical need","volume":"16","author":"Raffaeli","year":"2015","journal-title":"Pain Med. (Malden, Mass)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J069v25n02_01","article-title":"Antagonist treatment of opioid withdrawal translational low dose approach","volume":"25","author":"Mannelli","year":"2006","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.intimp.2018.05.020_bb0060","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.pnpbp.2008.02.004","article-title":"Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain","volume":"32","author":"Van Bockstaele","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.intimp.2018.05.020_bb0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/jcp.0b013e31814e5e9d","article-title":"Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence","volume":"27","author":"Mannelli","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/jpet.115.229542","article-title":"Combination of levo-tetrahydropalmatine and low dose naltrexone: a promising treatment for prevention of cocaine relapse","volume":"357","author":"Sushchyk","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2018.05.020_bb0075","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1007\/s00213-014-3519-0","article-title":"Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings","volume":"231","author":"Ray","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.intimp.2018.05.020_bb0080","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archinte.166.6.667","article-title":"A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation","volume":"166","author":"O'Malley","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.intimp.2018.05.020_bb0085","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.npp.1301243","article-title":"Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers","volume":"32","author":"Haney","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.intimp.2018.05.020_bb0090","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1126\/science.6867737","article-title":"Naltrexone modulates tumor response in mice with neuroblastoma","volume":"221","author":"Zagon","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.intimp.2018.05.020_bb0095","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.intimp.2013.10.012","article-title":"Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs)","volume":"17","author":"Meng","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.intimp.2016.08.015","article-title":"Functional modulation on macrophage by low dose naltrexone (LDN)","volume":"39","author":"Yi","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0105","first-page":"22","article-title":"Experimental study on the therapy of pancreatic cancer by combining methionine encephalin with low dose naltrexone","volume":"26","author":"Wang","year":"2018","journal-title":"Modern Oncol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0006-8993(87)91440-5","article-title":"Endogenous opioid systems regulate cell proliferation in the developing rat brain","volume":"412","author":"Zagon","year":"1987","journal-title":"Brain Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0165-0173(01)00160-6","article-title":"The biology of the opioid growth factor receptor (OGFr)","volume":"38","author":"Zagon","year":"2002","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.intimp.2018.05.020_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0006-8993(02)04172-0","article-title":"Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea","volume":"967","author":"Zagon","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/1535370213488483","article-title":"Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer","volume":"238","author":"Zagon","year":"2013","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/1535370213489492","article-title":"Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer","volume":"238","author":"Zagon","year":"2013","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0135","first-page":"991","article-title":"Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor","volume":"14","author":"McLaughlin","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ygyno.2011.04.009","article-title":"The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice","volume":"122","author":"Donahue","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0145","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bcp.2015.06.016","article-title":"Duration of opioid receptor blockade determines biotherapeutic response","volume":"97","author":"McLaughlin","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0150","first-page":"viii","volume":"236","year":"2011","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/ebm.2011.011321","article-title":"Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer","volume":"237","author":"Donahue","year":"2012","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0160","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1258\/ebm.2011.011121","article-title":"Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model","volume":"236","author":"Donahue","year":"2011","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0165","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.4161\/hv.28804","article-title":"Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs)","volume":"10","author":"Wang","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2018.05.020_bb0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2013.10.029","article-title":"Immunotherapy of cancer via mediation of cytotoxic T lymphocytes by methionine enkephalin (MENK)","volume":"344","author":"Li","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2018.05.020_bb0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0180","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11481-013-9451-y","article-title":"Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN)","volume":"8","author":"Chopra","year":"2013","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0185","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1213\/XAA.0000000000000292","article-title":"Identification and treatment of new inflammatory triggers for complex regional pain syndrome: small intestinal bacterial overgrowth and obstructive sleep apnea","volume":"6","author":"Weinstock","year":"2016","journal-title":"A & A Case Reports"},{"key":"10.1016\/j.intimp.2018.05.020_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.imbio.2010.06.001","article-title":"B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases","volume":"216","author":"Zagon","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2018.05.020_bb0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.imbio.2010.09.014","article-title":"T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases","volume":"216","author":"Zagon","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2018.05.020_bb0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/apc.1995.9.3","article-title":"Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV\/AIDS","volume":"9","author":"Bihari","year":"1995","journal-title":"AIDS Patient Care"},{"key":"10.1016\/j.intimp.2018.05.020_bb0205","first-page":"56","article-title":"MD: low-dose naltrexone for normalizing immune system function","volume":"19","author":"Bihari","year":"2013","journal-title":"Altern. Ther. Health Med."},{"key":"10.1016\/j.intimp.2018.05.020_bb0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1535370215596384","article-title":"Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4\u202f+\u202fT lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis","volume":"241","author":"Hammer","year":"2016","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0215","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3181\/0906-RM-189","article-title":"Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis","volume":"234","author":"Zagon","year":"2009","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0220","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbi.2011.12.010","article-title":"Mu opioid receptor activation modulates toll like receptor 4 in murine macrophages","volume":"26","author":"Franchi","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2018.05.020_bb0225","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hed.21759","article-title":"Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck","volume":"34","author":"McLaughlin","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.intimp.2018.05.020_bb0230","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.intimp.2018.05.020_bb0235","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neulet.2006.04.053","article-title":"Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice","volume":"403","author":"San-Emeterio","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.intimp.2018.05.020_bb0240","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.mehy.2006.04.015","article-title":"Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause?","volume":"67","author":"Good","year":"2006","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.intimp.2018.05.020_bb0245","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.mehy.2004.09.024","article-title":"Low dose naltrexone therapy in multiple sclerosis","volume":"64","author":"Agrawal","year":"2005","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.intimp.2018.05.020_bb0250","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1345\/aph.1H083","article-title":"Low-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed","volume":"41","author":"Patel","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.intimp.2018.05.020_bb0255","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458510366857","article-title":"The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial","volume":"16","author":"Sharafaddinzadeh","year":"2010","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0260","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/JCP.0000000000000373","article-title":"Low dose naltrexone for treatment of multiple sclerosis: a retrospective chart review of safety and tolerability","volume":"35","author":"Turel","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0270","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/1352458508095828","article-title":"A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis","volume":"14","author":"Gironi","year":"2008","journal-title":"Mult. Scler. (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0275","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.brainres.2011.01.036","article-title":"Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis","volume":"1381","author":"Rahn","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12865-015-0093-0","article-title":"Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis","volume":"16","author":"McLaughlin","year":"2015","journal-title":"BMC Immunol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0285","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1535370217724791","article-title":"Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone","volume":"242","author":"Ludwig","year":"2017","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0290","article-title":"Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis","volume":"2","author":"Ludwig","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.intimp.2018.05.020_bb0295","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-dose naltrexone therapy improves active Crohn's disease","volume":"102","author":"Smith","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0300","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ibd.21185","article-title":"Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient","volume":"16","author":"Shannon","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2018.05.020_bb0305","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","article-title":"Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study","volume":"47","author":"Smith","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0310","first-page":"Cd010410","article-title":"Low dose naltrexone for induction of remission in Crohn's disease","author":"Segal","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.intimp.2018.05.020_bb0315","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/MCG.0000000000000398","article-title":"Initial findings of an open-label trial of low-dose naltrexone for symptomatic mesenteric panniculitis","volume":"49","author":"Roginsky","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.npep.2016.06.003","article-title":"Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats","volume":"59","author":"Tawfik","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.intimp.2018.05.020_bb0325","first-page":"171","article-title":"Low dose naltrexone: side effects and efficacy in gastrointestinal disorders","volume":"14","author":"Ploesser","year":"2010","journal-title":"Int. J. Pharm. Compd."},{"key":"10.1016\/j.intimp.2018.05.020_bb0330","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0304-3959(99)00162-1","article-title":"Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study","volume":"83","author":"Yuan","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.intimp.2018.05.020_bb0335","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med. (Malden, Mass)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0340","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2018.05.020_bb0345","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.psym.2011.11.006","article-title":"Is fibromyalgia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option?","volume":"53","author":"Ramanathan","year":"2012","journal-title":"Psychosomatics"},{"key":"10.1016\/j.intimp.2018.05.020_bb0350","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13142-014-0282-z","article-title":"A control systems engineering approach for adaptive behavioral interventions: illustration with a fibromyalgia intervention","volume":"4","author":"Deshpande","year":"2014","journal-title":"Transl. Behav. Med."},{"key":"10.1016\/j.intimp.2018.05.020_bb0355","first-page":"209","article-title":"Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system","volume":"18","author":"Johnson","year":"2014","journal-title":"Discov. Med."},{"key":"10.1016\/j.intimp.2018.05.020_bb0360","first-page":"1","article-title":"Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia","volume":"5","author":"Parkitny","year":"2017","journal-title":"Biomedicine"},{"key":"10.1016\/j.intimp.2018.05.020_bb0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1573397111666150522095004","article-title":"Inflammatory fibromyalgia: is it real?","volume":"11","author":"Metyas","year":"2015","journal-title":"Curr. Rheumatol. Rev."},{"key":"10.1016\/j.intimp.2018.05.020_bb0370","first-page":"V03150248","article-title":"Low dose naltrexone for treatment of pain","volume":"177","author":"Plesner","year":"2015","journal-title":"Ugeskr. Laeger"},{"key":"10.1016\/j.intimp.2018.05.020_bb0375","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1001\/archophthalmol.2009.270","article-title":"Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus","volume":"127","author":"Zagon","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0380","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archopht.126.4.501","article-title":"Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone","volume":"126","author":"Zagon","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0385","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/1535370213492688","article-title":"Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis","volume":"238","author":"McLaughlin","year":"2013","journal-title":"Exp. Biol. Med. (Maywood, NJ)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0390","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.exer.2009.06.010","article-title":"Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats","volume":"89","author":"Klocek","year":"2009","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0395","first-page":"790","article-title":"Off-label, low-dose naltrexone for refractory painful diabetic neuropathy","volume":"17","author":"Hota","year":"2016","journal-title":"Pain Med. (Malden, Mass)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0400","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/804296","article-title":"Low-dose naltrexone for pruritus in systemic sclerosis","volume":"2011","author":"Frech","year":"2011","journal-title":"Int. J. Rheumatol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0405","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/14740338.2013.783564","article-title":"Oxycodone combined with opioid receptor antagonists: efficacy and safety","volume":"12","author":"Davis","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.intimp.2018.05.020_bb0410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0304-3835(03)00341-0","article-title":"Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice","volume":"199","author":"McLaughlin","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2018.05.020_bb0415","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1534735405285901","article-title":"The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid\/low-dose naltrexone protocol","volume":"5","author":"Berkson","year":"2006","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.intimp.2018.05.020_bb0420","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/1534735409352082","article-title":"Revisiting the ALA\/N (alpha-lipoic acid\/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases","volume":"8","author":"Berkson","year":"2009","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.intimp.2018.05.020_bb0425","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1534735407306358","article-title":"Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone","volume":"6","author":"Berkson","year":"2007","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.intimp.2018.05.020_bb0430","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10637-012-9918-3","article-title":"Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment","volume":"31","author":"Rogosnitzky","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.intimp.2018.05.020_bb0435","first-page":"973","article-title":"Metabolic treatment of cancer: intermediate results of a prospective case series","volume":"34","author":"Schwartz","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0440","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/ijo.2016.3567","article-title":"Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy","volume":"49","author":"Liu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0445","first-page":"189","article-title":"Synergistic effect of aged garlic extract and naltrexone on improving immune responses to experimentally induced fibrosarcoma tumor in BALB\/c mice","volume":"5","author":"Ebrahimpour","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0450","first-page":"721","article-title":"Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3\u2013a case report","volume":"13","author":"Khan","year":"2014","journal-title":"Oral Health Dent. Manag."},{"key":"10.1016\/j.intimp.2018.05.020_bb0455","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.20315","article-title":"Neuroglial activation and neuroinflammation in the brain of patients with autism","volume":"57","author":"Vargas","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0460","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0165-1781(95)02601-R","article-title":"Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study","volume":"58","author":"Bouvard","year":"1995","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.intimp.2018.05.020_bb0465","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00115-014-4015-9","article-title":"Low dose naltrexone in the treatment of dissociative symptoms","volume":"86","author":"Pape","year":"2015","journal-title":"Nervenarzt"},{"key":"10.1016\/j.intimp.2018.05.020_bb0470","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nlm.2013.09.002","article-title":"Divergent short- and long-term effects of acute stress in object recognition memory are mediated by endogenous opioid system activation","volume":"106","author":"Nava-Mesa","year":"2013","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.intimp.2018.05.020_bb0475","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/cap.1993.3.71","article-title":"Low-dose naltrexone inhibits pemoline-induced self-biting behavior in prepubertal rats","volume":"3","author":"King","year":"1993","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0480","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2016.08.029","article-title":"Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants","volume":"208","author":"Mischoulon","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.intimp.2018.05.020_bb0485","first-page":"43","article-title":"Neuroprotective effect of naloxone in inflammation-mediated dopaminergic neurodegeneration: dissociation from the involvement of opioid receptors","volume":"79","author":"Liu","year":"2003","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.intimp.2018.05.020_bb0490","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-2999(93)90246-E","article-title":"Peripheral mechanisms of opioid antinociception in inflammation- involvement of cytokines","volume":"242","author":"Andrzej","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0495","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/aim.2010.003566","article-title":"Enhancing acupuncture by low dose naltrexone","volume":"29","author":"Hesselink","year":"2011","journal-title":"Acupunct. Med."},{"key":"10.1016\/j.intimp.2018.05.020_bb0500","first-page":"197","article-title":"Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients","volume":"20","author":"Sturn","year":"2016","journal-title":"Int. J. Pharm. Compd."},{"key":"10.1016\/j.intimp.2018.05.020_bb0505","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/pme.12345","article-title":"Off-label, low-dose naltrexone for refractory chronic low back pain","volume":"15","author":"Ghai","year":"2014","journal-title":"Pain Med. (Malden, Mass)"},{"key":"10.1016\/j.intimp.2018.05.020_bb0510","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamadermatol.2017.2446","article-title":"Treatment of Hailey-Hailey disease with low-dose naltrexone","volume":"153","author":"Albers","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0515","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","article-title":"Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease)","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0520","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/pds.4110","article-title":"A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study","volume":"26","author":"Raknes","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.intimp.2018.05.020_bb0525","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2010.04.015","article-title":"Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial","volume":"111","author":"Toll","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.intimp.2018.05.020_bb0530","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-013-3036-6","article-title":"Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash","volume":"228","author":"Wright","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.intimp.2018.05.020_bb0535","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1037\/a0037223","article-title":"Effects of baclofen and naltrexone, alone and in combination, on the consumption of palatable food in male rats","volume":"22","author":"Avena","year":"2014","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0540","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/10837450.2014.915569","article-title":"Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6beta-naltrexol, using a novel LC Q-ToF MS assay","volume":"20","author":"Dodou","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.intimp.2018.05.020_bb0545","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jbm.a.32283","article-title":"Minor pathological changes are induced by naltrexone-poly(DL-lactide) implants in pregnant rats","volume":"91","author":"Farid","year":"2009","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.intimp.2018.05.020_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2017.04.012","article-title":"Potential drug interaction with opioid agonist in the setting of chronic low-dose opioid antagonist use","volume":"35","author":"Leonard","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.intimp.2018.05.020_bb0555","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s13311-017-0560-9","article-title":"Ethical considerations of patient-funded research for multiple sclerosis therapeutics","volume":"14","author":"Amezcua","year":"2017","journal-title":"Neurotherapeutics"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918302315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918302315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T09:42:38Z","timestamp":1720345358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576918302315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":111,"alternative-id":["S1567576918302315"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2018.05.020","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2018.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}